Huntington Disease Clinical Trial
Official title:
A Phase Ib/II Randomized, Double-Blind Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT 130) in Early Manifest Huntington's Disease
This is the second study of AMT-130 in patients with early manifest HD and is designed as part of an integrated two-study phase I/II program under a single data safety monitoring board (DSMB) with staggered enrollment based upon continued demonstration of safety of AMT-130 administration. Cohort 3 participants will receive either high or low dose (1:1 randomization). Participants enrolled in Cohort 3 will also receive an immunosuppression regimen consisting of dexamethasone, sirolimus, and rituximab.
Status | Recruiting |
Enrollment | 15 |
Est. completion date | October 7, 2029 |
Est. primary completion date | March 2029 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 25 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Able and willing to provide written informed consent prior to the study and study-related procedure. 2. Male and female participants 25-65 years of age. 3. Cohorts 1 & 2: 1. a DCL of 4 OR 2. a DCL of 3 with either a positive ("Yes") response to the UHDRS Question 80 (multidimensional manifest diagnosis on motor, cognitive, behavioral, functional) or DSM5 criteria for cognitive disorder (American Psychiatric Association, 2013; MDS Task Force criteria). 4. Cohort 3: 1. a DCL of 4 OR 2. a DCL of 3 with either a positive ("Yes") response to the UHDRS Question 80 (multidimensional manifest diagnosis on motor, cognitive, behavioral, functional) or DSM5 criteria for cognitive disorder (American Psychiatric Association, 2013; MDS Task Force criteria). 5. HTT gene expansion testing with the presence of =40 CAG repeats (confirmed by genetic testing at central laboratory). 6. Striatal MRI volume requirements per hemisphere: 1. Putamen =2.5 cm3 (per side) 2. Caudate =2.0 cm3 (per side) 7. All HD concomitant medications (addressing motor, behavioral and cognitive symptoms) must be stable for 3 months prior to Screening with no change in clinical symptoms requiring change in medication prior to anticipated administration procedure. 8. Able and willing to comply with all procedures and the study visit schedule as outlined in the protocol. 9. All female participants of childbearing potential (FCOP) must have negative serum pregnancy test at Screening (and Visit 1A, as appropriate), a negative pregnancy urine dipstick at Baseline, and not be breastfeeding. All FOCPs and sexually mature males must be compliant with highly effective birth control method as outlined in Section 4.5. Exclusion Criteria: 1. Evidence of suicide risk, defined as: 1. Suicide attempt within 1 year prior to Screening (Visit 1/1A) 2. Suicidal ideation as defined by a positive response to question 5 on Columbia-Suicide Severity Rating Scale (C-SSRS) Suicidal Ideation Section within 60 days prior to Screening (Visit 1/1A) 3. Significant risk of suicide as judged by the Investigator 2. Receipt of an experimental agent within 60 days or five half-lives prior to Screening or anytime over the duration of this study. 3. Participation in an investigational trial or investigational paradigm (such as exercise/physical activity, cognitive therapy, brain stimulation, etc.) within 60 days prior to Screening or anytime over the duration of this study. 4. Presence of an implanted deep brain stimulation device, ventriculoperitoneal or other CSF shunt, or other implanted catheter 5. Any history of gene therapy, RNA or DNA targeted HD specific investigational agents, such as antisense oligonucleotides (ASOs), cell transplantation or any other experimental brain surgery. 6. Any contraindication to lumbar puncture or 3.0 Tesla MRI as per local guidelines. 7. Brain and spinal pathology that may interfere with the surgical delivery of AMT-130 or represents a significant neurologic comorbid disorder. 8. Any contraindication to 3.0 Tesla MRI as per local guidelines 9. Malignancy within 5 years of screening, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated. 10. Hospitalization for any major medical or surgical procedure involving general anesthesia within 12 weeks of Screening or planned during the study. 11. Current or recurrent disease (including pre-existing cardiovascular or pulmonary conditions), infection, or other significant concurrent medical condition or medications that could confound clinical and laboratory evaluations or could affect a participant's safety or their ability to undergo a neurosurgical procedure (10+ hour surgical procedure) or comply with the procedures and study visit schedule. 12. Known or suspected intolerance or hypersensitivity to the investigational product(s), closely related compounds, or any of the stated ingredients. 13. Any known allergy to gadoteridol (ProHance). 14. Screening laboratory values (as measured by the central laboratory): 1. Alanine aminotransferase (ALT) >2 × upper limit of normal (ULN) 2. Aspartate aminotransferase (AST) >2 × ULN 3. Total bilirubin >2 × ULN 4. Alkaline phosphatase (ALP) >2 × ULN 5. Creatinine >1.5 × ULN 6. Platelet count <100,000/mm3 7. Prothrombin time (PT) >1.2 × ULN 8. Partial thromboplastin time (PTT) >1.2 × ULN 15. Known immunocompromised status including participants who have undergone organ transplantation or who test positive at Screening for the human immunodeficiency virus (HIV); or who are at risk of pathogen reactivation if immunosuppressed, including participants who test positive at screening for hepatitis C virus antibody (anti-HCV), hepatitis C virus ribonucleic acid (HCV RNA), hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (anti-HBc); or who have history of active tuberculosis or a positive tuberculosis blood test during screening. For participants with an indeterminate tuberculosis blood test result or positive tuberculosis test result, repeat testing is recommended. 16. Known allergy, sensitivity, or other contraindication to immunosuppression regimens in this protocol. 17. Any participant with an active infection (e.g., coronavirus disease 2019 [COVID-19]) at Screening or at the time of treatment that requires medical intervention. Participants may rescreen, or if screened eligible and an open surgical slot is available, may receive treatment after recovery. |
Country | Name | City | State |
---|---|---|---|
Germany | Universitaetsklinikum Düsseldorf | Düsseldorf | |
Germany | George Huntington Institute | Münster | |
Poland | Instytut Psychiatrii i Neurologii | Warsaw | |
Poland | Interventional Neuro Center | Warsaw | |
United Kingdom | Cardiff University | Cardiff | |
United Kingdom | National Hospital for Neurology & Neurosurgery | London |
Lead Sponsor | Collaborator |
---|---|
UniQure Biopharma B.V. |
Germany, Poland, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | CSF Mutant Protein (fM) | Will be used as an exploratory biomarker to measure disease progression and responsiveness to AMT-130 treatment. | Collected for duration of study through month 60 | |
Other | CSF/Serum Neurofilament Light Chain (pg/mL) | Will be used as an exploratory biomarker to measure disease progression and responsiveness to AMT-130 treatment. | Collected for duration of study through month 60 | |
Other | Mean changes from baseline in summary scores for the Unified Huntington Disease Rating Scale (UHDRS) | The UHDRS will assess changes from baseline in summary scores of domains of motor function, cognitive function, behavioral function, and functional abilities to capture the current disease status. | Collected for duration of study through month 60 | |
Other | Changes over time in Quantitative Motor (Q-Motor) Testing | Q-Motor testing will measure disease progression and responsiveness to AMT-130 treatment. | Collected for duration of study through month 60 | |
Other | Changes over time in Neurological Disorders Quality of Life in Neurological Disorder Measures (Neuro-QoL) | The Neuro-QoL is a brief, reliable, valid, standardized set of patient reported, Health Related Quality of Life (HRQoL) measures for people living with neurological conditions. | Collected for duration of study through month 60 | |
Other | Magnetic Resonance Imaging (MRI) - Brain Volumes | MRI assessments will include whole brain volume, striatal region volumes, white matter volume, gray matter volume, ventricular volume(cm^3) | Collected for duration of study through month 60 | |
Other | Magnetic Resonance Imaging (MRI) - Cortical Thickness | MRI assessments will include cortical thickness (mm) | Collected for duration of study through month 60 | |
Other | Diffusion Magnetic Resonance Imaging (MRI) | MRI assessments will include diffusion MRI measures mm2/s | Collected for duration of study through month 60 | |
Primary | Evaluate the safety and tolerability of bilateral striatal delivery of AMT-130 as a total HTT gene lowering therapy in adult subjects with early manifest HD assessed by Adverse Events | Evaluation will be assessed by;
- Type and incidence of Adverse Events (AEs) |
6 months | |
Primary | Evaluate the safety and tolerability of bilateral striatal delivery of AMT-130 as a total HTT gene lowering therapy in adult subjects with early manifest HD assessed by Vital Signs - Blood Pressure | Evaluation will be assessed by;
- Changes from baseline in blood pressure (mmHg) |
6 months | |
Primary | Evaluate the safety and tolerability of bilateral striatal delivery of AMT-130 as a total HTT gene lowering therapy in adult subjects with early manifest HD assessed by Vital Signs - Respiratory Rate | Evaluation will be assessed by;
- Changes from baseline in respiratory rate (BPM) |
6 months | |
Primary | Evaluate the safety and tolerability of bilateral striatal delivery of AMT-130 as a total HTT gene lowering therapy in adult subjects with early manifest HD assessed by Vital Signs - Heart Rate | Evaluation will be assessed by;
- Changes from baseline in heart rate (BPM) |
6 months | |
Primary | Evaluate the safety and tolerability of bilateral striatal delivery of AMT-130 as a total HTT gene lowering therapy in adult subjects with early manifest HD assessed by Electrocardiograms | Evaluation will be assessed by;
- Changes from baseline in electrocardiograms (ECGs) for any clinically significant abnormalities or clinically significant worsening. (normal or abnormal) |
6 months | |
Primary | Evaluate the safety and tolerability of bilateral striatal delivery of AMT-130 as a total HTT gene lowering therapy in adult subjects with early manifest HD assessed by changes documented in the neurological examinations | Evaluation will be assessed by;
- Changes from baseline in neurological examinations including mental status, cranial nerves, sensory, motor, fine motor, reflexes, and gait (normal or abnormal) |
6 months | |
Primary | Evaluate the safety and tolerability of bilateral striatal delivery of AMT-130 as a total HTT gene lowering therapy in adult subjects with early manifest HD assessed by changes documented in the physical examinations | Evaluation will be assessed by;
- Changes from baseline in physical examinations assessed by physical appearance, HEENT, Neck, Chest and Lungs, Cardiovascular, Abdomen, Musculoskeletal, and Genitourinary (normal or abnormal) |
6 months | |
Primary | Evaluate the safety and tolerability by number of participants with clinically significant changes in laboratory tests - Clinical Chemistry | Evaluation will be assessed by;
- Changes from baseline in Clinical Chemistry laboratory tests with clinical significance. |
6 months | |
Primary | Evaluate the safety and tolerability of bilateral striatal delivery of AMT-130 as a total HTT gene lowering therapy in adult subjects with early manifest HD assessed by number of participants with clinically significant laboratory tests - hematology | Evaluation will be assessed by;
- Changes from baseline in hematology laboratory tests with clinical significance. |
6 months | |
Primary | Evaluate the safety and tolerability of bilateral striatal delivery of AMT-130 as a total HTT gene lowering therapy in adult subjects with early manifest HD assessed by number of participants with clinical significant laboratory tests - urinalysis | Evaluation will be assessed by;
- Change from baseline in routine urinalysis test with clinical significance. |
6 months | |
Primary | Evaluate the safety and tolerability o by number of participants with clinical significant changes in cerebrospinal fluid (CSF) analysis | Evaluation will be assessed by;
- Change from baseline in CSF analysis with clinical significance. |
6 months | |
Primary | Evaluate the safety and tolerability of bilateral striatal delivery of AMT-130 as a total HTT gene lowering therapy in adult subjects with early manifest HD assessed by vector shedding | Evaluation will be assessed by;
- Change over time in AAV5 vector shedding |
6 months | |
Primary | Evaluate the safety and tolerability of bilateral striatal delivery of AMT-130 as a total HTT gene lowering therapy in adult subjects with early manifest HD assessed by laboratory testing serum and CSF for biomarkers | Evaluation will be assessed by;
- Change over time in microglial activation (YKL-40) (pg/mL) |
6 months | |
Primary | Evaluate the safety and tolerability of bilateral striatal delivery of AMT-130 as a total HTT gene lowering therapy in adult subjects with early manifest HD assessed by laboratory testing serum and CSF for biomarkers | Evaluation will be assessed by;
- Change over time in antibodies against AAV5 (g/L) |
6 months | |
Primary | Evaluate the safety and tolerability of bilateral striatal delivery of AMT-130 as a total HTT gene lowering therapy in adult subjects with early manifest HD assessed by laboratory testing serum and CSF for biomarkers | Evaluation will be assessed by;
- Change over time in cytokines (pg/mL) |
6 months | |
Primary | Evaluate the safety and tolerability of bilateral striatal delivery of AMT-130 as a total HTT gene lowering therapy in adult subjects with early manifest HD assessed by laboratory testing serum and CSF for biomarkers | Evaluation will be assessed by;
- Change over time in ELISpot |
6 months | |
Primary | Evaluate the safety and tolerability of bilateral striatal delivery of AMT-130 as a total HTT gene lowering therapy in adult subjects with early manifest HD assessed by laboratory testing serum and CSF for biomarkers | Evaluation will be assessed by;
- Change over time in astroglial activation (GFAP) (pg/mL) |
6 months | |
Primary | Evaluate the safety and tolerability of bilateral striatal delivery of AMT-130 as a total HTT gene lowering therapy in adult subjects with early manifest HD assessed by cognitive assessment | Evaluation will be assessed by;
- Change from baseline to Day 14 and Month 1 in the Montreal Cognitive Assessment (MoCA) |
6 months | |
Primary | Evaluate the safety and tolerability of bilateral striatal delivery of AMT-130 as a total HTT gene lowering therapy in adult subjects with early manifest HD assessed by number of participants with changes in MRI | Evaluation will be assessed by;
- Change from baseline will be measured by edema, inflammation, volume loss, and structural changes as measured by the following MRI pulse sequences, T1, T2 and diffusion MRI (dMRI) |
6 months | |
Secondary | Duration of persistence of AMT-130 in the brain | Change over time in levels of AMT-130-derived Vector DNA Expression in the Cerebrospinal Fluid (CSF) | Collected for duration of study through month 60 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Not yet recruiting |
NCT04429230 -
Non-invasive Brain Stimulation in Huntington's Disease
|
N/A | |
Recruiting |
NCT05032196 -
Study of WVE-003 in Patients With Huntington's Disease
|
Phase 1/Phase 2 | |
Recruiting |
NCT03599076 -
Wearable Sensors for Quantitative Assessment of Motor Impairment in Huntington's Disease Huntington's Disease
|
||
Terminated |
NCT04617860 -
Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT05748288 -
Development of the Virtual Unified Huntington's Disease Rating Scale
|
||
Not yet recruiting |
NCT05360082 -
Comparison Between [11C]UCB-J and [18F]SynVest-1 PET in HD.
|
||
Not yet recruiting |
NCT04370470 -
Development of Assessments for Later Stage HD
|
||
Recruiting |
NCT01834053 -
Safety and Efficacy of Bone Marrow Derived MNCs for Treatment of Cells for the Treatment of Hunting Tons Chorea.
|
Phase 1/Phase 2 | |
Completed |
NCT01458470 -
A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease
|
Phase 2 | |
Completed |
NCT01357681 -
Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study)
|
Phase 2 | |
Completed |
NCT00980694 -
Bioavailability of Ubiquinol in Huntington Disease
|
Phase 1 | |
Completed |
NCT00146211 -
TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease
|
Phase 3 | |
Recruiting |
NCT01412125 -
Study of Biomarkers That Predict the Evolution of Huntington's Disease
|
N/A | |
Completed |
NCT00075140 -
Family Health After Predictive Huntington Disease (HD) Testing
|
Phase 3 | |
Recruiting |
NCT04818060 -
Preparing for Prevention of Huntington's Disease (PREVENT-HD)
|
||
Active, not recruiting |
NCT04698551 -
NIPD on cffDNA for Triplet Repeat Diseases
|
||
Not yet recruiting |
NCT04301726 -
Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated With HD
|
Phase 1 | |
Completed |
NCT03421327 -
Genetic Risk: Whether, When, and How to Tell Adolescents
|
||
Recruiting |
NCT03296176 -
Metabolomic Study in Huntington's Disease (METABO-HD)
|
N/A |